DV
Dividend Vision

TARS — Tarsus Pharmaceuticals, Inc.

Tarsus Pharmaceuticals, Inc. (TARS)

Total return is 236.2% over the past 5.8 years, 94.4 points ahead of SPY at 141.8%. Its deepest 1-year drawdown was 32.0%.

This is a single-stock equity holding in Tarsus Pharmaceuticals, a healthcare company, rather than a diversified ETF. The holding pays no distributions and carries no reported expense ratio or stated fund objective, indicating this is a direct stock position rather than a traditional ETF structure. This holding appeals primarily to investors seeking direct exposure to a specific pharmaceutical company rather than those pursuing dividend income or broad sector diversification.

TARS key facts

Asset type
Stock
Asset class
Equity
Inception date
10/16/2020
Distribution frequency
None
Last close
$69.20
Market cap
$3,036,703,232
Average volume
448300.0
Beta
0.512
Payout ratio
0.0
Forward P/E
106.383
EPS
$-1.07